Amin Li
Impact in
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
-
- Nanoparticle-Based Drug Delivery
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 5
- Ubiquitin and proteasome pathways 2
- Wnt/β-catenin signaling in development and cancer 2
-
- Hepatocellular Carcinoma Treatment and Prognosis 5
- Liver physiology and pathology 3
- Co-authors
- Yinci Zhang (14 shared papers)Xinkuang Liu (8 shared papers)Ruyue Xu (10 shared papers)Xueke Liu (7 shared papers)Yong Liang (5 shared papers)Yongfang Ma (9 shared papers)Weiya Cao (9 shared papers)Shuping Zhou (8 shared papers)
- Journals
- PLoS ONE (2 papers)Cancer Research (2 papers)Drug Delivery (1 paper)Nanoscale Research Letters (1 paper)Journal of Molecular Medicine (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Amin Li
21 papers receiving 417 citations
Peers
Comparison fields: 5 of 57
- Hepatology 66
- Biomaterials 83
- Cancer Research 65
- Pathology and Forensic Medicine 76
- Molecular Medicine 16
Countries citing papers authored by Amin Li
This map shows the geographic impact of Amin Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amin Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amin Li more than expected).
Fields of papers citing papers by Amin Li
This network shows the impact of papers produced by Amin Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amin Li. The network helps show where Amin Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Amin Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 56 | |
| 2 | 2018 | 45 | |
| 3 | PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway. | 2019 | 36 |
| 4 | BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway. | 2019 | 29 |
| 5 | 2021 | 29 | |
| 6 | 2022 | 27 | |
| 7 | 2021 | 25 | |
| 8 | 2018 | 23 | |
| 9 | 2020 | 22 | |
| 10 | BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway. | 2019 | 20 |
| 11 | 2021 | 19 | |
| 12 | 2020 | 19 | |
| 13 | 2021 | 19 | |
| 14 | 2020 | 14 | |
| 15 | 2022 | 13 | |
| 16 | 2018 | 10 | |
| 17 | 2024 | 5 | |
| 18 | 2007 | 5 | |
| 19 | 2023 | 3 | |
| 20 | 2020 | 1 |
About Amin Li
Amin Li is a scholar working on Molecular Biology, Hepatology, Pathology and Forensic Medicine, Oncology and Cancer Research, having authored 26 papers that have together received 421 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Liver physiology and pathology (3 papers), Nanoparticle-Based Drug Delivery (3 papers), Cancer Mechanisms and Therapy (3 papers), Ubiquitin and proteasome pathways (2 papers), Cancer, Lipids, and Metabolism (2 papers) and Wnt/β-catenin signaling in development and cancer (2 papers). The work is most often cited by research in Hepatology (66 citations), Biomaterials (83 citations), Cancer Research (65 citations), Pathology and Forensic Medicine (76 citations) and Molecular Medicine (16 citations). Amin Li has collaborated with scholars based in China and United States. Frequent co-authors include Yinci Zhang, Xinkuang Liu, Ruyue Xu, Xueke Liu, Yong Liang, Yongfang Ma, Weiya Cao, Shuping Zhou, Xiaolong Tang and Dong Ma. Their work appears in journals such as PLoS ONE, Cancer Research, Drug Delivery, Nanoscale Research Letters and Journal of Molecular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.